|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016441,
umls-concept:C0022646,
umls-concept:C0023981,
umls-concept:C0026933,
umls-concept:C0205210,
umls-concept:C0332157,
umls-concept:C0450127,
umls-concept:C0521116,
umls-concept:C1514721,
umls-concept:C1521840,
umls-concept:C1705413,
umls-concept:C1709854
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-5-23
|
|
pubmed:abstractText |
Two recent randomized clinical trials--Fixed Dose Versus Concentration Controlled and the Apomygre--evaluating the benefit of therapeutic drug monitoring of mycophenolate mofetil (MMF) in renal allograft recipients reported conflicting results. In both studies, target mycophenolic acid (MPA) AUC(0-12 h) ranges (ie, values used to guide MMF dosing) were derived from a previous study establishing target MPA AUC(0-12 h) ranges in cyclosporine-treated patients between 30 and 60 mg/L x h(-1). Both studies found an association between MPA exposure and acute rejection. However, only one of the studies found concentration-controlled MMF dosing to be significantly associated with less biopsy-proven acute-rejection episodes compared with fixed dosing. No reduced incidence of MMF-related adverse events (AEs) was observed in either of the 2 trials when MMF concentration-controlled and fixed dosing were compared.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
673-83
|
|
pubmed:meshHeading |
pubmed-meshheading:18498916-Anemia,
pubmed-meshheading:18498916-Chromatography, High Pressure Liquid,
pubmed-meshheading:18498916-DNA,
pubmed-meshheading:18498916-Drug Resistance, Multiple,
pubmed-meshheading:18498916-Enzyme Inhibitors,
pubmed-meshheading:18498916-Female,
pubmed-meshheading:18498916-Follow-Up Studies,
pubmed-meshheading:18498916-Glucuronosyltransferase,
pubmed-meshheading:18498916-Graft Rejection,
pubmed-meshheading:18498916-Humans,
pubmed-meshheading:18498916-Immunoassay,
pubmed-meshheading:18498916-Kidney Transplantation,
pubmed-meshheading:18498916-Leukopenia,
pubmed-meshheading:18498916-Male,
pubmed-meshheading:18498916-Middle Aged,
pubmed-meshheading:18498916-Multidrug Resistance-Associated Proteins,
pubmed-meshheading:18498916-Mycophenolic Acid,
pubmed-meshheading:18498916-Polymerase Chain Reaction,
pubmed-meshheading:18498916-Polymorphism, Single Nucleotide,
pubmed-meshheading:18498916-Prospective Studies,
pubmed-meshheading:18498916-Time Factors,
pubmed-meshheading:18498916-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
|
|
pubmed:affiliation |
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium. Dirk.Kuypers@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial
|
